Corporate Finance & Consulting  
 
 
Home Page > Replicon Group
 



Results from Client Survey
29-10-2008, ph

As part of its continuous service development process, Replicon ordered an independent survey on client needs and level of satisfaction. This first study was directed to Health Care and Life Science sector companies. Later we plan to extend similar surveys to cover also ICT sector companies and possibly all leading Finnish growth companies.

Underlying theme of the survey was to find out the need and willingness to use outsourced financial and strategic services in general. We also asked what are the main competences that weigh when selecting an adviser.

Other part of the questionnaire was related to Replicon services, their pricing and customer satisfaction. We are very happy to say that almost all of the feed back related to Replicon and its services was positive. Please find summarised results of the survey below:

Questions and recorded responses:

1) 70 % of respondents have used or are planning to use an outside financial expert.

2) Somewhat surprisingly most respondents thought that sector specific knowledge was not very important when selecting financial adviser. Most important selection criteria was to use local expertise followed by well known brand and references of the adviser.

3) Replicon was well known among respondents. Some 70 % of the respondents knew Replicon.

4) Most well known Replicon services were valuations and technology evaluations. Only second came advisory in financial and M&A arrangements.

5) Quality of Replicon services:

Customer service: 15 % over expectations, 57% good, 28% didn’t know,
Use of local investors: 43% good, 57% didn’t express their opinion,
Use of local and foreign collaboration networks: 46% good or satisfactory, 54% didn’t express their opinion,
Ability to reach goals: 15% over expectations, 30% good or satisfying, rest didn’t express their opinion.

6) Pricing of Replicon services

Competitivity: 15% better than expected, 46% good or satifying, 39% didn’t know,
Price – quality ratio: 15% better than expected, 31% good or satisfying, rest didn’t know,
Clear principles in pricing: 46 % were satisfied, rest didn’t express their opinion,
Terms of the payments: 31 % good or satisfactory, 15% didn’t meet expectations, rest didn’t express their opinion.

The survey was conducted by Stellaria Media (www.stellariamedia.fi). The questionnaire was sent to more than 100 Finnish Life Science sector and Health Care companies and organizations.

For further information on Replicon services, please contact Replicon Group professionals:

firstname.lastname [at] replicon.fi
or call +358-(0)9-677 464

About Replicon

Replicon Group is an independent advisory house for growth companies and growth investors. We are a Certified Adviser (CA) in Nasdaq OMX First North market place. Replicon provides financial, strategic and legal solutions that facilitate business activities, efficiency, and increase profitability of corporations and other organizations. Our core competence is in the corporate solutions that facilitate and govern growth of businesses based on innovation. An important part of our activities is continuous learning. We want to find and develop most suitable solutions to our customer needs. Replicon’s homepage is www.replicon.fi

Replicon: “One Stop Shop for Growth Company financing and M&A”


Recent articles:

> 19-08-2010 - Valuation Services and Total Life Cycle Cost Analyses

> 04-05-2010 - Oversol Oy / Lumi Group Oy Raises First Part of 2-4 M€ Financing

> 22-03-2010 - Replicon Continues as Certified Adviser in NASDAQ OMX First North

> 22-03-2010 - Replicon Group jatkaa NASDAQ OMX:ssä neuvonantajana

> 22-01-2010 - Replicon Initiates Multimillion Financing Project for Promising LED Application

> 06-10-2009 - Replicon Newsletter Q3/2009

> 09-09-2009 - New Certification for Replicon Group

> 24-08-2009 - Replicon toimittaa asiantuntija-palvelupaketin Qentinel Oy:lle

> 17-08-2009 - ASIAVIIHDE: videoidut talouskirja-arvostelut

> 16-06-2009 - Replicon Group Company Awarded 2 Year R&D Project

> 21-05-2009 - Replicon Newsletter Q2/2009

> 21-05-2009 - Repliconin Uutiskirje Q2/2009

> 03-02-2009 - Replicon Newsletter Q1/2009

> 19-01-2009 - Jouko Ahvenainen Presenting in Mobile World Congress in Barcelona

> 19-12-2008 - Replicon Creates an Option Arrangement for Its Client

> 29-10-2008 - Results from Client Survey

> 18-09-2008 - Tuottavuus ja rahoitus 2008 -seminaari

> 17-06-2008 - Ani Biotech buys the Business Operations of Orgenium Laboratories

> 20-05-2008 - Tietoisku FIRST NORTH -markkinapaikasta

> 31-03-2008 - Replicon Collaboration Partner Forms Global Multi-Centre Network

> 30-01-2008 - Replicon helps EVE to Receive Private Equity Financing

> 29-01-2008 - Replicon Pharma Portfolio Outperforms Benchmark Index Fifth Year in a Row

> 29-11-2007 - Replicon Group OMX First Northin Certified Adviseriksi

> 29-11-2007 - Replicon Group becomes Certified Adviser in OMX First North

> 28-11-2007 - Matti Copeland Repliconin neuvonantajaksi

> 15-10-2007 - Replicon Private Equity -tapahtuma

> 24-09-2007 - Talentor Receives Private Equity Financing Package in Record Time

> 07-08-2007 - Meet Replicon in Autumn 2007

> 11-05-2007 - Replicon and Imanext Form Strategic Collaboration

> 17-04-2007 - Pääjohtaja Liikanen puhumassa Repliconin Tuottavuus -seminaarissa

> 17-04-2007 - BoF Governor Speaking at Replicon Productivity Seminar

> 09-03-2007 - Top Seminar: ICT Companies as Productivity Boosters

> 08-03-2007 - Xtract raises € 2 million in venture capital funding from Eqvitec

> 21-02-2007 - ICT-yritykset tuottavuuden nostajina - Repliconin Tuottavuus ja rahoitus -seminaari 17.4.2007

> 29-01-2007 - Replicon MDF Portfolio Outperforms Benchmark Index Fourth Year in a Row

> 29-01-2007 - Repliconin Pharma portfolio (MDF) ylittänyt jälleen vertailuindeksin tuoton

> 08-01-2007 - Replicon toimittaa asiantuntijapalvelupaketin Qentinel Oy:lle

> 15-12-2006 - Replicon Provides Expert Services for Xtract, Ltd.

> 01-11-2006 - Replicon Provides Compensation Arrangement Planning for Growth Companies

> 01-11-2006 - Replicon toteuttaa osakesidonnaisia kannustinjärjestelmiä kasvuyrityksille

> 26-10-2006 - Petteri Hirvonen Presenting in Global UMTS TDD Alliance Summit in London

> 28-09-2006 - Jouko Ahvenainen Presenting in Mobile Marketing Service Summit in Lisbon

> 29-05-2006 - First Half Management Consulting Projects of Replicon

> 01-04-2006 - Replicon Launches Investigational Asset Management Portfolio in ICT sector

> 02-03-2006 - Enfucell Receives First VC Round of Financing

> 20-02-2006 - Replicon Helps Arranging Significant Financing Package for a Client

> 29-01-2006 - Replicon Portfolio Outperforms Benchmark Third Year in a Row

> 02-01-2006 - Replicon Hires Satu Vapaakallio as Analyst

> 24-11-2005 - Replicon Initiate 7.5Meur Private Placement Process for SkyWeb Oy

> 14-10-2005 - CTT Cancer Targeting Technologies Ltd enters into R&D agreement with GE Healthcare

> 05-09-2005 - Orgenium receives financing from Abroad and Expands Production to Low Cost Production Site in Ankara, Turkey

> 20-07-2005 - Replicon helps arranging financing for #CMAX.gg

> 31-03-2005 - Replicon in BioFinland 05 Investor Forum

> 29-01-2005 - Replicon Biotech Value Portfolio Outperforms NASDAQ Biotech Index Second Year in a Row

> 26-01-2005 - Replicon Extends Its Life Science Expert Team

> 18-01-2005 - All Replicon Senior Partners Gain Accreditation by the Ministry of Trade and Industry

> 10-01-2005 - Jouko Ahvenainen (MBA, M.Sc.) joins Replicon as a Senior Partner

> 17-12-2004 - Replicon to Develop a Model for Enhancing Commercialization of Bone Research in Finland

> 29-10-2004 - Replicon moves to WTC Helsinki

> 15-10-2004 - MBA Petri Laulajainen joins Replicon as a Senior Partner

> 02-07-2004 - Orgenium closes financing round with private investors and Finnish Industry Investment Ltd.

> 27-05-2004 - Replicon's new strategic partners announced

> 07-04-2004 - Viope closes financing round for expansion

> 29-01-2004 - Replicon Biotech Model Portfolio Annual Return 78 per cent

> 15-12-2003 - Replicon enters into a two-year business development partnership

> 19-08-2003 - Dr. Hannu Silvennoinen joins as a Senior Partner

> 09-04-2003 - Replicon forms corporate finance unit

> 28-01-2003 - Replicon Launches Model Portfolio in Biotech

 
© 2003, Replicon